Literature DB >> 24091928

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Giovanni Di Minno1, Mariana Canaro, James W Ironside, David Navarro, Carlo Federico Perno, Andreas Tiede, Lutz Gürtler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24091928      PMCID： PMC3789452          DOI： 10.3324/haematol.2013.084145

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States.

Authors:  T L Chorba; R C Holman; M J Clarke; B L Evatt
Journal:  Am J Hematol       Date:  2001-04       Impact factor: 10.047

2.  Emerging and re-emerging viruses in the era of globalisation.

Authors:  Alessandra Zappa; Antonella Amendola; Luisa Romanò; Alessandro Zanetti
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

3.  New perspectives in hemophilia treatment.

Authors:  Craig M Kessler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

Review 4.  HLA-B27 and host-pathogen interaction.

Authors:  Anna S Sahlberg; Kaisa Granfors; Markus A Penttinen
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

5.  Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients.

Authors:  Dietje E Fransen van de Putte; Kathelijn Fischer; Astrid E Pulles; Goris Roosendaal; Douwe H Biesma; Roger E G Schutgens; Eveline P Mauser-Bunschoten
Journal:  Thromb Res       Date:  2011-12-30       Impact factor: 3.944

6.  Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990.

Authors:  James J Goedert; Bingshu E Chen; Liliana Preiss; Louis M Aledort; Philip S Rosenberg
Journal:  Am J Epidemiol       Date:  2007-03-22       Impact factor: 4.897

7.  Mortality and causes of death in Italian persons with haemophilia, 1990-2007.

Authors:  A Tagliaferri; G F Rivolta; A Iorio; E Oliovecchio; M E Mancuso; M Morfini; A Rocino; M G Mazzucconi; M Franchini; N Ciavarella; A Scaraggi; L Valdrè; G Tagariello; P Radossi; G Muleo; P G Iannaccaro; C Biasoli; D Vincenzi; M L Serino; S Linari; C Molinari; E Boeri; M La Pecorella; M T Carloni; E Santagostino; G Di Minno; A Coppola; A Rocino; E Zanon; L Spiezia; C Di Perna; M Marchesini; M Marcucci; A Dragani; S Macchi; P Albertini; M D'Incà; C Santoro; F Biondo; G Piseddu; G Rossetti; G Barillari; G Gandini; A C Giuffrida; G Castaman
Journal:  Haemophilia       Date:  2010-02-09       Impact factor: 4.287

8.  Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.

Authors:  Valentina Svicher; Valeria Cento; Martina Bernassola; Maria Neumann-Fraune; Formijn Van Hemert; Mengjie Chen; Romina Salpini; Chang Liu; Roberta Longo; Michela Visca; Sara Romano; Valeria Micheli; Ada Bertoli; Caterina Gori; Francesca Ceccherini-Silberstein; Cesare Sarrecchia; Massimo Andreoni; Mario Angelico; Antonella Ursitti; Alberto Spanò; Jing Maria Zhang; Jens Verheyen; Giuseppina Cappiello; Carlo Federico Perno
Journal:  Antiviral Res       Date:  2011-11-09       Impact factor: 5.970

Review 9.  Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Authors:  Leopold Grillberger; Thomas R Kreil; Sonia Nasr; Manfred Reiter
Journal:  Biotechnol J       Date:  2009-02       Impact factor: 4.677

Review 10.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162
View more
  10 in total

1.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 2.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

3.  Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Authors:  R Kulkarni; R J Presley; J M Lusher; A D Shapiro; J C Gill; M Manco-Johnson; M A Koerper; T C Abshire; D DiMichele; W K Hoots; P Mathew; D J Nugent; S Geraghty; B L Evatt; J M Soucie
Journal:  Haemophilia       Date:  2016-11-04       Impact factor: 4.287

Review 4.  Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.

Authors:  Alessandro Di Minno; Monica Gelzo; Marianna Caterino; Michele Costanzo; Margherita Ruoppolo; Giuseppe Castaldo
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

5.  Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Authors:  Joan C Gill; Giancarlo Castaman; Jerzy Windyga; Peter Kouides; Margaret Ragni; Frank W G Leebeek; Ortrun Obermann-Slupetzky; Miranda Chapman; Sandor Fritsch; Borislava G Pavlova; Isabella Presch; Bruce Ewenstein
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

Review 6.  Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Authors:  Giovanni Di Minno; David Navarro; Carlo Federico Perno; Mariana Canaro; Lutz Gürtler; James W Ironside; Hermann Eichler; Andreas Tiede
Journal:  Ann Hematol       Date:  2017-06-18       Impact factor: 3.673

Review 7.  Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Clin Med       Date:  2017-04-10       Impact factor: 4.241

Review 8.  Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  Ther Clin Risk Manag       Date:  2016-06-30       Impact factor: 2.423

Review 9.  Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.

Authors:  Claudia Djambas Khayat
Journal:  J Blood Med       Date:  2016-11-30

Review 10.  Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.

Authors:  Giovanni Di Minno; Carlo Federico Perno; Andreas Tiede; David Navarro; Mariana Canaro; Lutz Güertler; James W Ironside
Journal:  Blood Rev       Date:  2015-07-20       Impact factor: 8.250
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.